Table Info

Table 1.

ADCs in MM

Target	Agent	Active key trials (phase)	Prior lines	Regimen	Toxicities (≥ grade 3)
BCMA	Belantamab mafodotin	NCT03715478 (Ph I/II)	RRMM	+ Pom/Dex	Keratopathy/MEC, ↓ VA, neutropenia, thrombocytopenia, lung infection, dyspnea
		NCT03848845 DREAMM-4 (Ph II)	RRMM	+ Pembrolizumab	-
		NCT04126200 DREAMM-5 (Ph II)	3 or more	+/− GSK3174998 or +/− GSK3359609 or +/− nirogacestat or +/− dostarlimab	-
		NCT03544281 DREAMM-6 (Ph II)	RRMM	+ Len/Dex or + Bor/Dex	Keratopathy/MEC, thrombocytopenia
		NCT04484623 DREAMM-8 (Ph III)	1 or more	+ Pom/Dex	-
		NCT04091126 DREAMM-9 (Ph III)	TI-NDMM	+/− Bor/Len/Dex	-
		NCT04398745 DREAMM-12 (Ph I)	2 or more	Single agent	-
		NCT04177823 (Ph I)	2 or more	Single agent	-
	MEDI2228	NCT03489525	RRMM	Single agent	Thrombocytopenia, pleural effusion, rash, transaminitis
	AMG 224	NCT02561962 (Ph I)	3 or more	Single agent	Thrombocytopenia, transaminitis, fatigue, nausea, anemia
CD38 (ADC)	TAK-169	NCT04017130 (Ph I)	2 or more	Single agent	-
CD38 (ADC)	TAK-573	NCT03215030 (Ph I/II)	3 or more	+/− Dex	-
CD46 (ADC)	FOR46	NCT03650491 (Ph I)	RRMM	Single agent	-
CD74 (ADC)	STRO-001	NCT03424603 (Ph I)	RRMM	Single agent	-

↓: decreased; -: not applicable; Ph: clinical trial phase; TI-NDMM: transplant-ineligible newly diagnosed MM; MEC: microcyst- like epithelial changes; VA: visual acuity

Declarations

Acknowledgments

The authors would like to thank the Department of Medicine, Division of Medical Oncology, Dana-Farber Cancer Institute for its support.

Author contributions

Both authors, MHB and PR, contributed to the drafting, revising, and editing of the manuscript. Both authors contributed to the conception and design of the manuscript as well as approval of the definitive version to be published. Both authors agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. MHB contributed as the primary author contributed most of the work. PR, as senior author, edited and contributed some of the written work.

Conflicts of interest

Monique Hartley-Brown has received consulting fees from the following companies: GlaskoSmithKline, Janssen, Bristol Myers Squibb, Cardinal Health, and Karyopharm. Paul Richardson has received grant support and honoraria for service on advisory committees from Celgene/BMS, Karyopharm, Oncopeptides, and Takeda, and honoraria for service on advisory committees from Janssen, Sanofi, and Secura Bio.

Ethical approval

Not applicable.

Consent to participate

Not applicable.

Consent to publication

Not applicable.

Availability of data and materials

Not applicable.

Funding

Not applicable.

Copyright

References

Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos MV, et al. International myeloma working group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15:e538–48. [DOI] [PubMed]

Cohen AD, Raje N, Fowler JA, Mezzi K, Scott EC, Dhodapkar MV. How to train your T cells: overcoming immune dysfunction in multiple myeloma. Clin Cancer Res. 2020;26:1541–54. [DOI] [PubMed] [PMC]

Palumbo A, Bertola A, Musto P, Caravita T, Callea V, Nunzi M, et al. Oral melphalan, prednisone, and thalidomide for newly diagnosed patients with myeloma. Cancer. 2005;104:1428–33. [DOI] [PubMed]

Richardson PG, Schlossman R, Hideshima T, Anderson KC. New treatments for multiple myeloma. Oncology (Williston Park). 2005;19:1781–92; discussion 1792, 1795–7. [PubMed]

Cohen AD. Myeloma: next generation immunotherapy. Hematology Am Soc Hematol Educ Program. 2019;2019:266–72. [DOI] [PubMed] [PMC]

Birrer MJ, Moore KN, Betella I, Bates RC. Antibody-drug conjugate-based therapeutics: state of the science. J Natl Cancer Inst. 2019;111:538–49. [DOI] [PubMed]

Chau CH, Steeg PS, Figg WD. Antibody-drug conjugates for cancer. Lancet. 2019;394:793–804. [DOI] [PubMed]

Markham A. Belantamab mafodotin: first approval. Drugs. 2020;80:1607–13. [DOI] [PubMed]

Tai YT, Anderson KC. B cell maturation antigen (BCMA)-based immunotherapy for multiple myeloma. Expert Opin Biol Ther. 2019;19:1143–56. [DOI] [PubMed] [PMC]

10.

Shah N, Chari A, Scott E, Mezzi K, Usmani SZ. B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches. Leukemia. 2020;34:985–1005. [DOI] [PubMed] [PMC]

11.

Cho SF, Anderson KC, Tai YT. Targeting B cell maturation antigen (BCMA) in multiple myeloma: potential uses of BCMA-based immunotherapy. Front Immunol. 2018;9:1821. [DOI] [PubMed] [PMC]

12.

Tzogani K, Penttilä K, Lähteenvuo J, Lapveteläinen T, Lopez Anglada L, Prieto C, et al. EMA review of belantamab mafodotin (blenrep) for the treatment of adult patients with relapsed/refractory multiple myeloma. Oncologist. 2021;26:70–6. [DOI] [PubMed] [PMC]

13.

Lonial S, Lee HC, Badros A, Trudel S, Nooka AK, Chari A, et al. Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study. Lancet Oncol. 2020;21:207–21. [DOI]

14.

Trudel S, Davis R, Lewis NM, Bakshi KK, Chopra B, De Oca RM, et al. DREAMM-8: a phase III study of the efficacy and safety of belantamab mafodotin with pomalidomide and dexamethasone (B-Pd) vs pomalidomide plus bortezomib and dexamethasone (PVd) in patients with relapsed/refractory multiple myeloma (RRMM). Blood. 2020;136:4. [DOI]

15.

Trudel S, Lendvai N, Popat R, Voorhees PM, Reeves B, Libby EN, et al. Targeting B-cell maturation antigen with GSK2857916 antibody-drug conjugate in relapsed or refractory multiple myeloma (BMA117159): a dose escalation and expansion phase 1 trial. Lancet Oncol. 2018;19:1641–53. [DOI] [PubMed] [PMC]

16.

Usmani SZ, Terpos E, Janowski W, Quach H, West S, Williams D, et al. DREAMM-9: phase III study of belantamab mafodotin plus VRd versus VRd alone in transplant-ineligible newly diagnosed multiple myeloma (TI NDMM). J Clin Oncol. 2020;38:TPS8556. [DOI]

17.

Trudel S, Nooka A, Fecteau D, Talekar M, Jewell RC, Williams D, et al. DREAMM 4: a phase I/II single-arm open-label study to explore safety and clinical activity of belantamab mafodotin (GSK2857916) administered in combination with pembrolizumab in patients with relapsed/refractory multiple myeloma (RRMM). Ann Oncol. 2019;30:v447. [DOI]

18.

Richardson PG, Biswas S, Holkova B, Jackson N, Netherway T, Bao W, et al. Dreamm-5: platform trial evaluating belantamab mafodotin (a BCMA-directed Immuno-conjugate) in combination with novel agents in relapsed or refractory multiple myeloma (RRMM). Blood. 2019;134:1857. [DOI]

19.

Popat R, Nooka A, Stockerl-Goldstein K, Abonour R, Ramaekers R, Khot A, et al. DREAMM-6: safety, tolerability and clinical activity of belantamab mafodotin (belamaf) in combination with bortezomib/dexamethasone (BorDex) in relapsed/refractory multiple myeloma (RRMM). Blood. 2020;136:19–30. [DOI]

20.

Xing L, Li Y, Lin L, Yu T, Wen K, Cho S, et al. MEDI2228, a novel bcma antibody-PBD conjugate, sensitizes human multiple myeloma cells to NK cell-mediated cytotoxicity and upregulates CD38 expression in MM cells. Blood. 2019;134:3096. [DOI]

21.

Tai YT, Acharya C, An G, Moschetta M, Zhong MY, Feng X, et al. APRIL and BCMA promote human multiple myeloma growth and immunosuppression in the bone marrow microenvironment. Blood. 2016;127:3225–36. [DOI] [PubMed] [PMC]

22.

Kumar SK, Migkou M, Bhutani M, Spencer A, Ailawadhi S, Kalff A, et al. Phase 1, first-in-human study of MEDI2228, a BCMA-targeted ADC in patients with relapsed/refractory multiple myeloma. Blood. 2020;136:26–7. [DOI]

23.

Lee HC, Raje NS, Landgren O, Upreti VV, Wang J, Avilion AA, et al. Phase 1 study of the anti-BCMA antibody-drug conjugate AMG 224 in patients with relapsed/refractory multiple myeloma. Leukemia. 2021;35:255–8. [DOI] [PubMed]

24.

Willert EK, Robinson GL, Higgins JP, Liu J, Lee J, Syed S, et al. Abstract 2384: TAK-169, an exceptionally potent CD38 targeted engineered toxin body, as a novel direct cell kill approach for the treatment of multiple myeloma. Cancer Res. 2019;79:2384. [DOI]

25.

Vogl DT, Kaufman JL, Holstein SA, Nadeem O, O’Donnell E, Suryanarayan K, et al. TAK-573, an anti-CD38/attenuated ifnα fusion protein, has clinical activity and modulates the ifnα receptor (IFNAR) pathway in patients with relapsed/refractory multiple myeloma. Blood. 2020;136:37–8. [DOI]

26.

VanWyngarden M, Walker Z, Su Y, Bearrows S, Stevens B, Forsberg P, et al. CD46 antibody drug conjugate impedes myeloma engraftment in patient-derived xenografts. Clin Lymphoma Myeloma Leuk. 2019;19:e151. [DOI]

27.

Abrahams CL, Li X, Embry M, Yu A, Krimm S, Krueger S, et al. Targeting CD74 in multiple myeloma with the novel, site-specific antibody-drug conjugate STRO-001. Oncotarget. 2018;9:37700–14. [DOI] [PubMed] [PMC]

28.

Shah NN, Krishnan AY, Shah ND, Burke JM, Melear JM, Spira AI, et al. Preliminary results of a phase 1 dose escalation study of the first-in-class anti-CD74 antibody drug conjugate (ADC), STRO-001, in patients with advanced B-cell malignancies. Blood. 2019;134:5329. [DOI]

29.

Figueroa-Vazquez V, Ko J, Breunig C, Baumann A, Giesen N, Pálfi A, et al. HDP-101, an anti-BCMA antibody-drug conjugate, safely delivers amanitin to induce cell death in proliferating and resting multiple myeloma cells. Mol Cancer Ther. 2021;20:367–78. [DOI] [PubMed]

30.

Singh RK, Jones RJ, Shirazi F, Hong S, Wang H, Wan J, et al. HDP-101, a novel BCMA-targeted antibody conjugated to α -amanitin, is active against myeloma with preferential efficacy against pre-clinical models of deletion 17p. Clin Lymphoma Myeloma Leuk. 2019;19:e152. [DOI]

31.

Ko J, Breunig C, Figueroa V, Lehners N, Baumann A, Pálfi A, et al. Preclinical evaluation of HDP-101, a novel anti-BCMA antibody-drug conjugate, in multiple myeloma. Blood. 2017;130:3070.

32.

Ikeda H, Hideshima T, Fulciniti M, Lutz RJ, Yasui H, Okawa Y, et al. The monoclonal antibody nBT062 conjugated to cytotoxic maytansinoids has selective cytotoxicity against CD138-positive multiple myeloma cells in vitro and in vivo. Clin Cancer Res. 2009;15:4028–37. [DOI] [PubMed]

33.

Jagannath S, Heffner LT Jr, Ailawadhi S, Munshi NC, Zimmerman TM, Rosenblatt J, et al. Indatuximab ravtansine (BT062) monotherapy in patients with relapsed and/or refractory multiple myeloma. Clin Lymphoma Myeloma Leuk. 2019;19:372–80. [DOI] [PubMed]

34.

Ailawadhi S, Kelly KR, Vescio RA, Jagannath S, Wolf J, Gharibo M, et al. A phase I study to assess the safety and pharmacokinetics of single-agent lorvotuzumab mertansine (IMGN901) in patients with relapsed and/or refractory CD-56-positive multiple myeloma. Clin Lymphoma Myeloma Leuk. 2019;19:29–34. [DOI] [PubMed]

35.

Berdeja JG. Lorvotuzumab mertansine: antibody-drug-conjugate for CD56⁺ multiple myeloma. Front Biosci (Landmark Ed). 2014;19:163–70. [DOI] [PubMed]

36.

Kaufman JL, Niesvizky R, Stadtmauer EA, Chanan-Khan A, Siegel D, Horne H, et al. Phase I, multicentre, dose-escalation trial of monotherapy with milatuzumab (humanized anti-CD74 monoclonal antibody) in relapsed or refractory multiple myeloma. Br J Haematol. 2013;163:478–86. [DOI] [PubMed]

37.

Mark T, Martin P, Leonard JP, Niesvizky R. Milatuzumab: a promising new agent for the treatment of lymphoid malignancies. Expert Opin Investig Drugs. 2009;18:99–104. [DOI] [PubMed]

38.

Costa LJ, Wong SW, Bermúdez A, de la Rubia J, Mateos MV, Ocio EM, et al. First clinical study of the B-cell maturation antigen (BCMA) 2 + 1 T cell engager (TCE) CC-93269 in patients (Pts) with relapsed/refractory multiple myeloma (RRMM): interim results of a phase 1 multicenter trial. Blood. 2019;134:143. [DOI]

39.

Richardson PG, San Miguel JF, Moreau P, Hajek R, Dimopoulos MA, Laubach JP, et al. Interpreting clinical trial data in multiple myeloma: translating findings to the real-world setting. Blood Cancer J. 2018;8:109. [DOI] [PubMed] [PMC]